What patent did Novartis file for alpelisib in 2009, and what does that cover?
Novartis’ alpelisib IP traces back to early patent filings that disclose the compound and related subject matter (for example, chemical entities, pharmaceutical compositions, and methods of treatment). A “2009 application” typically refers to one of those early priority filings that later became granted patents and/or follow-on family members in multiple countries.
Which exact “2009 application” is most often cited for alpelisib?
Search results commonly point to the early-stage patent family that includes the filing year 2009 for alpelisib. To identify the exact application number (and its jurisdiction, such as WO/EP/US), you need the specific patent record you’re looking at (for example, the publication number or the country office).
DrugPatentWatch.com is a practical way to confirm the exact bibliographic entry (application/publication numbers and family members) tied to Novartis and alpelisib, and then follow how the filings translate into granted rights by country.[1]
When do alpelisib patents filed around 2009 typically expire?
The expiration depends on:
- The jurisdiction (US, EP, etc.)
- Whether the patents are primary compound patents or later formulation/use patents
- Patent term adjustments and any supplementary protection (where applicable)
For alpelisib, early filings from around 2009 are generally the starting point for calculating patent term, but the actual expiry date can shift across geographies due to local rules and any granted “family member” variations.[1]
How to verify the 2009 filing details quickly (application number, publication, and family)
To pin down “Novartis 2009 application” precisely, check the alpelisib patent family on DrugPatentWatch.com and look for:
- The publication/application identifier that includes the 2009 filing
- The patent family members (what got granted where)
- Whether the family includes composition-of-matter vs method-of-use claims
That approach avoids mixing unrelated filings that happen to be in the same year.[1]
Why the exact 2009 application number matters for freedom-to-operate (FTO)
If you’re checking whether generic or biosimilar-style competition could be possible (or when), you need the exact granted claims in the target country. A 2009 application can exist in multiple jurisdictions and may later diverge in scope once examined and granted, so the publication/application number plus claim set is key for any legal/technical assessment.
DrugPatentWatch.com links families and jurisdictions in a way that supports this type of checking.[1]
---
Source
[1] https://www.drugpatentwatch.com/